tranilast Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tranilast is an antiallergic drug. It was developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in the 1980s.   Wikipedia

Chemistry

  • SMILES: COc1ccc(\C=C\C(=O)Nc2ccccc2C(=O)O)cc1OC
  • InChIKey: NZHGWWWHIYHZNX-CSKARUKUSA-N
  • Mol. Mass: 327.34
  • ALogP: 3.05
  • ChEMBL Molecule:
    tranilast  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

2-((3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid | mk-341 | n-(3,4-dimethoxycinnamoyl)anthranilic acid | n-(3',4'-dimethoxycinnamoyl)anthranilic acid | rizaben | tranilast | tranilast hydrate | tranilast sodium | tranilast sodium salt | tranilastum

Organizations (11)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (1)


 

Hypersensitivity

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Arthritis, Rheumatoid (Phase 2)

Conjunctivitis, Allergic (Phase 4)

C-Reactive Protein (Phase 4)

Cryopyrin-Associated Periodic Syndromes (Phase 2)

Gout (Phase 2)

Hypersensitivity, Immediate ()

Hyperuricemia (Phase 2)

Inflammasomes (Phase 4)

Mucinoses (Early Phase 1)

Nasopharyngeal Carcinoma (Phase 2)

Neoplasms (Phase 2)

Percutaneous Coronary Intervention (Phase 4)

Pterygium (Phase 3)

Sarcoidosis (Early Phase 1)

Scleredema Adultorum (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue